0001214659-23-010923.txt : 20230809
0001214659-23-010923.hdr.sgml : 20230809
20230809163026
ACCESSION NUMBER: 0001214659-23-010923
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230809
FILED AS OF DATE: 20230809
DATE AS OF CHANGE: 20230809
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TOTH A ERNEST JR
CENTRAL INDEX KEY: 0001280273
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38599
FILM NUMBER: 231155660
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aquestive Therapeutics, Inc.
CENTRAL INDEX KEY: 0001398733
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208623253
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 30 TECHNOLOGY DRIVE
CITY: WARREN
STATE: NJ
ZIP: 07059
BUSINESS PHONE: 908-941-1900
MAIL ADDRESS:
STREET 1: 30 TECHNOLOGY DRIVE
CITY: WARREN
STATE: NJ
ZIP: 07059
FORMER COMPANY:
FORMER CONFORMED NAME: MonoSol Rx, Inc.
DATE OF NAME CHANGE: 20070507
4
1
marketforms-61879.xml
PRIMARY DOCUMENT
X0508
4
2023-08-09
0001398733
Aquestive Therapeutics, Inc.
AQST
0001280273
TOTH A ERNEST JR
C/O AQUESTIVE THERAPEUTICS, INC.
30 TECHNOLOGY DRIVE
WARREN
NJ
07059
false
true
false
false
SVP, Chief Financial Officer
0
Performance Stock Units
2023-08-09
4
A
false
70000
0
A
2026-05-05
Common Stock
70000
70000
D
Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.
/s/ Lori J. Braender, as Attorney-In-Fact
2023-08-09